Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avecho BiotechnologyASX:AVE EV-to-EBITDA is -21.05 as of Aug. 10, 2026. The stock has 2 warning signs investors should review. Among 400 Biotechnology companies, Avecho Biotechnology ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avecho Biotechnology's enterprise value is A$80.35 Mil.
Avecho Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.82 Mil. Therefore, Avecho Biotechnology's EV-to-EBITDA for today is -21.05.
The historical rank and industry rank for Avecho Biotechnology's EV-to-EBITDA or its related term are showing as below:
ASX:AVE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.05 Med: -1.55 Max: 27.61
Current: -21.05
During the past 13 years, the highest EV-to-EBITDA of Avecho Biotechnology was 27.61. The lowest was -21.05. And the median was -1.55.
ASX:AVE's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.065
vs ASX:AVE: -21.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avecho Biotechnology's PE Ratio (TTM) for today is calculated as:
Avecho Biotechnology's share price for today is A$0.022.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Avecho Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVE vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Avecho Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's EV-to-EBITDA falls into.
Avecho Biotechnology's current Enterprise Value is A$80.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology (ASX:AVE) has a EV-to-EBITDA of -21.05 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avecho Biotechnology. According to the industry distribution chart, Avecho Biotechnology ranks #999999 out of 400 companies in the Biotechnology industry.
Is Avecho Biotechnology's EV-to-EBITDA too high?
Avecho Biotechnology's current EV-to-EBITDA is -21.05. Based on the distribution chart, Avecho Biotechnology ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Avecho Biotechnology's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #999999 out of 400 companies for EV-to-EBITDA. This places Avecho Biotechnology in the lower half of its industry. The industry median EV-to-EBITDA is 13.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.07, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avecho Biotechnology. For the Biotechnology industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avecho Biotechnology's current EV-to-EBITDA is -21.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current EV-to-EBITDA of -21.05. The current EV-to-EBITDA is -21.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current EV-to-EBITDA is -21.05 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 
